Document Detail

Thyroid remnant ablation in patients with papillary cancer: a comparison of low, moderate, and high activities of radioiodine.
MedLine Citation:
PMID:  19247212     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The consensus about optimal activities of I-131 for thyroid remnant ablation has not yet been achieved. The aim of this study was to compare ablation rates obtained with different I-131 activities. PATIENTS AND METHODS: The study included 466 patients divided into four groups according to I-131 activities given after total thyroidectomy for papillary thyroid cancer: group A [168 patients who received 888 MBq (24 mCi)], group B [125 patients who received 1480 MBq (40 mCi)], group C [65 patients who received 1850 MBq (50 mCi)], and group D [108 patients who received 4440 MBq (120 mCi)]. Ablation outcome was assessed by whole-body scan in hypothyroid state 6-9 months after ablation and finally 18-21 months after the treatment. RESULTS: The rate of successful ablation was similar in the group of patients who received 24 and 40 mCi (75 and 71.2%, respectively). The higher rate of ablation was achieved in the groups treated with 50 and 120 mCi of radioiodine (87.69 and 90.74%, respectively). The ablation rates at the first follow-up examinations (59.5, 67.2, 73.9, 80.6%) were lower than at second control study (75.0, 71.2, 87.7, 90.7%) in all groups. Time required for thyroid remnant ablation seems to be >or=18 months. CONCLUSION: Our study indicates that activity of 50 mCi seems to be optimal to achieve a successful ablation rate (approximately 90%). Low I-131 activities are acceptable for lower risk patients because of satisfactory ablation rate (>70%), lower expense, and minimal radiation burden to patients as well as lower radiation exposure to clinical staff. The ablative use of high activities seems neither justified nor optimized.
Sanja Kusacic Kuna; Tatjana Samardzic; Vanja Tesic; Mario Medvedec; Krunoslav Kuna; Irena Bracic; Marija Despot; Damir Dodig
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Nuclear medicine communications     Volume:  30     ISSN:  0143-3636     ISO Abbreviation:  Nucl Med Commun     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-09     Completed Date:  2009-05-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8201017     Medline TA:  Nucl Med Commun     Country:  England    
Other Details:
Languages:  eng     Pagination:  263-9     Citation Subset:  IM    
Clinical Department of Nuclear Medicine and Radiation Protection, Clinical Hospital Centre Zagreb, Zagreb, Croatia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carcinoma, Papillary / radionuclide imaging,  radiotherapy*,  surgery*
Iodine Radioisotopes / therapeutic use*
Middle Aged
Radiopharmaceuticals / therapeutic use
Thyroid Gland / radionuclide imaging,  surgery*
Thyroid Neoplasms / radionuclide imaging,  radiotherapy*,  surgery*
Thyrotropin / blood
Treatment Outcome
Whole Body Imaging
Young Adult
Reg. No./Substance:
0/Iodine Radioisotopes; 0/Radiopharmaceuticals; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid.
Next Document:  Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation...